bluebird bio, Inc. has announced the filing by 2seventy bio of an updated Form 10 Registration Statement with the U.S. Securities and Exchange Commission (SEC).
Sophiris Bio Inc.developing PRX 302 (topsalysin) for the treatment of symptoms of Benign Prostatic Hyperplasia (BPH, enlarged prostate) and the...
Sesen Bio reported positive preliminary efficacy data for the primary endpoint of its ongoing Phase III registration trial, the VISTA...
Sophiris Bio a biopharmaceutical company developing PRX 302 (topsalysin) for the treatment of urological diseases, announced final results from its...
Bio Products Laboratory Limited has presented new data from TEN02, the Phase III, prospective study of Coagadex (Coagulation Factor X,...
Treatment has begun of the first patient in Northstar-2, the Phase III study of the LentiGlobin drug product from bluebird...
Biogen Inc. and Bio-Thera Solutions, Ltd. presented positive Phase III data for BIIB 800 (BAT1806), a biosimilar candidate referencing Actemra/Roactemra (tocilizumab), anti-interleukin-6 receptor monoclonal antibody, at the Annual European Congress of Rheumatology (EULAR 2022).
The FDA has accepted for filing a supplemental Biologics License Application (BLA) for Coagadex (Coagulation Factor X, Human), from Bio...
bluebird bio, Inc.announced that the European Medicines Agency (EMA) accepted the company�s marketing authorization application (MAA) for its investigational LentiGlobin...
Sesen Bio announced that the Company has submitted its Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for Vicineum (oportuzumab monatox) for the treatment of high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) under the EMA’s centralized procedure.